Novel targets for anti-retroviral therapy

Journal of Infection

Volumn 59, Issue 6, 2009, Pages 377-386

  Bhattacharya, Sanjay ^a   Osman, Husam ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

CCR5; Drug design; HIV; Integrase; Maturation inhibitors; Novel targets

Indexed keywords

8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ANTIRETROVIRUS AGENT; APLAVIROC; APRICITABINE; ATAZANAVIR; AZOFORMAMIDE; BEVIRIMAT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; GSK 873140; HGTV 43; IBALIZUMAB; KP 1461; LOPINAVIR PLUS RITONAVIR; MARAVIROC; PLACEBO; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RITONAVIR PLUS TIPRANAVIR; ROSCOVITINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VICRIVIROC;

ABDOMINAL DISTENSION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; AMYLASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CYSTITIS; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GLUCOSE INTOLERANCE; HALF LIFE TIME; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIVER TOXICITY; MUSCLE SPASM; NEPHROLITHIASIS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PLASMA HALF LIFE; REVIEW; SEIZURE; SIDE EFFECT; SYNCOPE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE INHIBITORS; SUCCINATES; TRITERPENES;

EID: 71549124948     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.09.014     Document Type: Review

References (74)

1. Cane P., Chrystie I., Dunn D., Evans B., Geretti A.M., Green H., et al. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331 (2005) 1368
2. Friis-Møller N., Sabin C.A., Weber R., d'Arminio Monforte A., El-Sadr W.M., Reiss P., et al., for the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349 (2003) 1993-2003
3. 9 cells/L. Ann Intern Med 139 (2003) 810-816
4. Wensing A.M.J., van de Vijver D.A., Gioacchino A., Asjö B., Balotta C., Boeri E., et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192 (2005) 958-966
5. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 (2002) 181-188
6. Claxton A.J., Cramer J., and Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23 (2001) 1296-1310
7. Maggiolo F., Ravasio L., Ripamonti D., Gregis G., Quinzan G., Arici C., et al. Similar adherence rates favour different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 40 (2005) 158-163
8. UNAIDS. Joint United Nations Programme on HIV/AIDS. Report on global AIDS epidemic. Executive summary (July 2008). http://data.unaids.org/pub/GlobalReport/2008/JC1511_GR08_ExecutiveSummary_en.pdf [accessed on 13.08.09]
9. Rawlins M.D. Nat Rev Drug Discov 3 (2004) 360-364
10. Auclair J.R., Green K.M., Shandilya S., Evans J.E., Somasundaran M., and Schiffer C.A. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 69 (2007) 270-284
11. Hornak V., and Simmerling C. Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today 12 (2007) 132-138
12. Klei H.E., Kish K., Lin P.F., Guo Q., Friborg J., Rose R.E., et al. X-ray Crystal structures of HIV-1 protease mutants Complexed with atazanavir. J Virol 81 (2007) 9525-9535
13. Kuntz I.D. Structure-Based strategies for drug design and discovery. Science 257 (1992) 1078-1082
14. Lind K.E., Du Z., Fujinaga K., Peterlin B.M., and James T.L. Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem Biol 9 (2002) 185-193
15. Lutzke R.A., and Plasterk R.H. HIV integrase: a target for drug discovery. Genes Funct 1 (1997) 289-307
16. Henry C. Structure-based drug design. Chem Eng News 79 (2001) 69-74
17. Clavel F., and Hance A.J. HIV drug resistance. N Engl J Med 350 (2004) 1023-1035
18. Reynes J., Arastéh K., Clotet B., Cohen C., Cooper D.A., Delfraissy J.F., et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 21 (2007) 533-543
19. Cahn P., Cassetti I., Wood R., Phanuphak P., Shiveley L., Bethell R.C., and Sawyer J. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20 (2006) 1261-1268
20. Murphy RL, Schurmann D, Beard A, et al. Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; San Francisco, California; February 8-11, 2004. [abstract 137].
21. Murakami E., Basavapathruni A., Bradley W.D., and Anderson K.S. Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases. Antivir Res 67 (2005) 10-17
22. Herzmann C., Arasteh K., Murphy R.L., Schulbin H., Kreckel P., Drauz D., et al. Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naive human immunodeficiency virus-infected patients. Antimicrobial Agents Chemother 49 (2005) 2828-2833
23. Dutschman G.E., Grill S.P., Gullen E.A., Haraguchi K., Takeda S., Tanaka H., et al. Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 48 (2004) 1640-1646
24. Goebel F., Yakovlev A., Pozniak A.L., Vinogradova E., Boogaerts G., Hoetelmans R., et al. Short-term antiviral activity of TMC278-a novel NNRTI-in treatment-naive HIV-1-infected subjects. AIDS 20 (2006) 1721-1726
25. Grossman HA, Hicks C, Nadler J, et al. Efficacy and tolerability of TMC125 in HIV Patients with NNRTI and PI Resistance at 24 Weeks: TMC125-C223. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC; 2005. [abstract H-416c]
26. Lazzarin A, Queiroz-Telles F, Frank I, et al. TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. Program and abstracts of the XVI International AIDS Conference: Toronto, Canada. ; August 13-18, 2006. [abstract TUAB0104]
27. Lazzarin, et al. Tipranavir/ritonavir (TPV/r) demonstrates superior treatment response to lopinavir/r (LPV/r), amprenavir/r (APV/r) or saquinavir/r (SQV/r) in PI-experienced patients from the TPV RESIST-1 and RESIST-2 trials. Abstract WePe6.3C07. Program and Abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment: Rio de Janeiro, Brazil; July 24-27, 2005.
28. GlaxoSmithKline. Statement to HIV Patient Community: Information from GlaxoSmithKline on Changes to Studies of Investigational CCR5 Entry Inhibitor Aplaviroc (GW873140). September 15, 2005.
29. European Medicines Agency. www.emea.europa.eu/humandocs/PDFs/EPAR/celsentri/H-811-en6.pdf [accessed on 16.04.09]
30. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359 (2008) 1429-1441
31. Moyle G, DeJesus E, Boffito M, et al. CXCR4 antagonism: proof of activity with AMD11070. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections: Los Angeles, California; February 25-28, 2007 [abstract 511].
32. Mori J., Mosley M., Lewis M., et al. Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2. Antivir Ther 12 (2007) S12 [abstract 10]
33. Schering-Plough. Schering-Plough Expands vicriviroc phase II study in treatment-naive patients with HIV. http://www.schering-plough.com/news/news_article.aspx?reqid=1307827 [accessed 12.09.09]
34. AIDS Info. Vicriviroc maleate. http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailT.aspx?int_id=405 [accessed 12.09.09]
35. Tagat J.R., McCombie S.W., Nazareno D., Labroli M.A., Xiao Y., Steensma R.W., et al. Piperazine-Based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(R)- 4-(trifluoromethyl)phenyl}ethyl-3(S)- methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly Selective, and orally Bioavailable CCR5 antagonist. J Med Chem 47 (2004) 2405-2408
36. Nichols W.G., Steel H.M., Bonny T., Adkison K., Curtis L., Millard J., et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother 52 (2008) 858-865
37. Cao Y.J., Flexner C.W., Dunaway S., Park J.G., Klingman K., Wiggins I., et al. Effect of low-dose ritonavir on the pharmacokinetics of the CXCR4 antagonist AMD070 in healthy volunteers. Antimicrob Agents Chemother 52 (2008) 1630-1634
38. Wong R, Bodart V, Metz M, Labrecque J, Bridger G, Fricker S. Understanding the interactions between CXCR4 and AMD11070, a first-in-class small molecule antagonist of the HIV coreceptor. Poster 495. In: 14th Conference of Retrovirus and Opportunistic infections. Los Angeles; 25-28 February, 2007.
39. Esposito D., and Craigie R. HIV integrase structure and function. Adv Virus Res 52 (1999) 319-333
40. Hicks C., and Gulick R.M. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis 48 (2009) 931-939
41. Cooper D, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles: California; February 25-28, 2007 [abstracts 105aLB].
42. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, California ; February 25-28, 2007 [abstracts 105bLB].
43. Zolopa A, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patients. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections: Los Angeles, California ; February 25-28, 2007 [abstract 143LB].
44. U.S. Food and Drug Administration. Isentress (raltegravir) indication extended for the treatment of HIV-1 infection in treatment-naïve patients. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm171317.htm [accessed 12.09.09]
45. Malet I., Delelis O., Valantin M.A., Montes B., Soulie C., Wirden M., et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52 (2008) 1351-1358
46. Klibanov O.M. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs 10 (2009) 190-200
47. DeJesus E., Berger D., Markowitz M., Cohen C., Hawkins T., Ruane P., et al., for the 183-0101 Study Team. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 1-5
48. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82 (2008) 764-774
49. Martin D.E., Blum R., Wilton J., Doto J., Galbraith H., Burgess G.L., et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 51 (2007) 3063-3066
50. Beatty G, Lalezari J, Eron J, et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. Program and abstracts of the 45th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy: Washington, DC; December 16-19, 2005 [abstract H-416d].
51. Smith P, Forrest A, Beatty G, et al. Pharmacokinetics/pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections: Denver, Colorado; February 5-8, 2006 [abstract 52].
52. Adamson C, Salzwedel K, Castillo A, et al. Viral resistance to PA-457, a novel inhibitor of HIV-1 maturation. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections: Denver, Colorado; February 5-8, 2006 [abstract 156].
53. Schito M.L., Soloff A.C., Slovitz D., Trichel A., Inman J.K., Appella E., et al. Preclinical evaluation of a zinc finger inhibitor targeting lentivirus nucleocapsid protein in SIV-infected monkeys. Curr HIV Res 4 (2006) 379-386
54. Schito M.L., Goel A., Song Y., Inman J.K., Fattah R.J., Rice W.G., et al. In vivo antiviral activity of novel human immunodeficiency virus type 1 nucleocapsid p7 zinc finger inhibitors in a transgenic murine model. AIDS Res Hum Retroviruses 19 (2003) 91-101
55. Rice W.G., Baker D.C., Schaeffer C.A., Graham L., Bu M., Terpening S., et al. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 41 (1997) 419-426
56. Goebel F.D., Hemmer R., Schmit J.C., Bogner J.R., de Clercq E., Witvrouw M., et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 15 (2001) 33-45
57. Pumfery A., de la Fuente C., Berro R., Nekhai S., Kashanchi F., and Chao S.H. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics. Curr Pharm Des 12 (2006) 1949-1961
58. de la Fuente C., Maddukuri A., Kehn K., Baylor S.Y., Deng L., Pumfery A., and Kashanchi F. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics. Curr HIV Res 1 (2003) 131-152
59. Schang L.M., Bantly A., Knockaert M., Shaheen F., Meijer L., Malim M.H., et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 76 (2002) 7874-7882
60. Wang D., de la Fuente C., Deng L., Wang L., Zilberman I., Eadie C., et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 75 (2001) 7266-7279
61. Richter S., Parolin C., Gatto B., Del Vecchio C., Brocca-Cofano E., Fravolini A., et al. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 48 (2004) 1895-1899
62. Yang M. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disord 5 (2005) 433-444
63. Yuan D., He M., Pang R., Lin S.S., Li Z., and Yang M. The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors. Bioorg Med Chem 15 (2007) 265-272
64. Gu S., Ji J., Kim J.D., Yee J.K., and Rossi J.J. Inhibition of infectious human immunodeficiency virus type 1 virions via lentiviral vector encoded short antisense RNAs. Oligonucleotides 16 (2006) 287-295
65. Jakobsen M.R., Haasnoot J., Wengel J., Berkhout B., and Kjems J. Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology 264 (2007) 29
66. Lebars I., Richard T., Di Primo C., and Toulmé J.J. LNA derivatives of a kissing aptamer targeted to the trans-activating responsive RNA element of HIV-1. Blood Cells Mol Dis 38 (2007) 204-209
67. Lu X., Yu Q., Binder G.K., Chen Z., Slepushkina T., Rossi J., and Dropulic B. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 78 (2004) 7079-7088
68. Haasnoot J., Westerhout E.M., and Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 25 (2007) 1435-1443
69. Kuritzkes D.R., Jacobson J., Powderly W.G., Godofsky E., DeJesus E., Haas F., et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 189 (2004) 286-291
70. Zhang X.Q., Sorensen M., Fung M., and Schooley R.T. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 50 (2006) 2231-2233
71. Harris K.S., Brabant W., Styrchak S., Gall A., and Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antivir Res 67 (2005) 1-9
72. Wang F.X., Xu Y., Sullivan J., Souder E., Argyris E.G., Acheampong E.A., et al. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest 115 (2005) 128-137
73. Lehrman G., Hogue I.B., Palmer S., Jennings C., Spina C.A., Wiegand A., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 (2005) 549-555
74. Smith S.M. Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2 (2005) 56